Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Krystal Biotech (KRYS) Leases (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Leases for 5 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Leases rose 15.27% to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 15.27% year-over-year, with the annual reading at $7.2 million for FY2025, 15.27% up from the prior year.
  • Leases hit $7.2 million in Q4 2025 for Krystal Biotech, down from $7.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $8.5 million in Q1 2022 to a low of $3.2 million in Q1 2021.
  • Historically, Leases has averaged $7.2 million across 5 years, with a median of $7.4 million in 2021.
  • Biggest five-year swings in Leases: surged 164.16% in 2022 and later fell 12.62% in 2023.
  • Year by year, Leases stood at $7.2 million in 2021, then rose by 11.26% to $8.0 million in 2022, then decreased by 12.62% to $7.0 million in 2023, then fell by 10.63% to $6.3 million in 2024, then increased by 15.27% to $7.2 million in 2025.
  • Business Quant data shows Leases for KRYS at $7.2 million in Q4 2025, $7.4 million in Q3 2025, and $7.7 million in Q2 2025.